Physician profile
Michael Scarbrough
NPI 1114345949
$15,415.81
in general payments reported to CMS, 2019-2025
28 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,415 · 2020: $855 · 2021: $1,144 · 2022: $1,846 · 2023: $957 · 2024: $4,964 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,001 · Travel and Lodging: $3,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,001.19 |
| Travel and Lodging | $3,154.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $2,993.03 | 2019-2020 | |
| Boston Scientific Corporation | $2,926.45 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Stryker Corporation | $2,644.51 | 2023-2025 | Augment Injectable, Mild Device Kit, Spinejack |
| Medtronic, INC. | $2,074.92 | 2021-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Accurian |
| Nevro Corp. | $1,594.14 | 2019-2024 | Senza |
| Gentleman Orthopedic Solutions | $575.29 | 2019 | |
| Amgen INC. | $430.79 | 2021-2023 | Aimovig |
| Abbvie INC. | $391.55 | 2021-2022 | |
| Spr Therapeutics, INC | $357.84 | 2020-2025 | Sprint Pns System |
| Abbott Laboratories | $241.87 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $195.11 | 2019-2023 | Ztlido |
| Collegium Pharmaceutical, INC. | $169.81 | 2021-2024 | Xtampza, Belbuca |
| Biohaven Pharmaceuticals, INC. | $118.05 | 2021 | |
| Curonix LLC | $100.00 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Globus Medical, INC. | $79.82 | 2025 | Senza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $73.54 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $71.48 | 2022 | |
| Pfizer INC. | $67.14 | 2019-2021 | |
| Vertiflex, INC. | $64.13 | 2019 | |
| Grt US Holding, INC. | $45.59 | 2021-2022 | |
| Horizon Therapeutics Plc | $32.27 | 2022 | |
| Relievant Medsystems, INC. | $31.76 | 2022-2023 | Intracept |
| Teva Pharmaceuticals USA, INC. | $31.40 | 2020 | |
| Arthrex, INC. | $30.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.47 | 2021-2022 | |
| Nalu Medical, INC. | $16.07 | 2023 | Nalu Neurostimulation System |
| Lilly USA, LLC | $15.33 | 2019 | |
| Allergan, INC. | $14.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Scarbrough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.